Imfinzi (durvalumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Imfinzi (durvalumab) is a human monoclonal antibody and an immunotherapy medication developed to inhibit programmed death-ligand 1 (PD-L1), a protein that cancer cells use to evade the immune system. It is indicated for the treatment of several cancers, including non-small cell lung cancer, small cell lung cancer, biliary tract cancer, and advanced urothelial carcinoma.

The main types of Imfinzi (durvalumab) include 2.4 mL injections and 10 mL injections. A 2.4 mL injection refers to a defined volume of the medication supplied in a 2.4 milliliter vial or syringe, commonly used to ensure accurate dosing in clinical treatments or procedures. These formulations are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used for various applications such as locally advanced urothelial carcinoma, metastatic urothelial carcinoma, and others.

Tariffs have impacted the Imfinzi market by increasing costs related to monoclonal antibody production inputs, sterile injection packaging, and temperature controlled logistics. These impacts are most evident in regions reliant on imported biologics such as asia pacific and eastern europe. Hospital oncology budgets face pricing pressures due to higher acquisition costs. At the same time, tariffs have encouraged regional biologics manufacturing investments. This improves long term supply stability and reduces dependence on global trade routes.

The imfinzi (durvalumab) market research report is one of a series of new reports from The Business Research Company that provides imfinzi (durvalumab) market statistics, including imfinzi (durvalumab) industry global market size, regional shares, competitors with a imfinzi (durvalumab) market share, detailed imfinzi (durvalumab) market segments, market trends and opportunities, and any further data you may need to thrive in the imfinzi (durvalumab) industry. This imfinzi (durvalumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The imfinzi (durvalumab) market size has grown rapidly in recent years. It will grow from $3.01 million in 2025 to $3.36 million in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to clinical success of immune checkpoint inhibitors, rising lung cancer prevalence, regulatory approvals in oncology, improved survival outcomes, strong pharmaceutical investment.

The imfinzi (durvalumab) market size is expected to see rapid growth in the next few years. It will grow to $5.11 million in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to expansion into new cancer indications, increased immunotherapy accessibility, growth in oncology clinical trials, rising healthcare oncology spending, development of combination protocols. Major trends in the forecast period include rising adoption of pd-l1 inhibitors, expansion of immunotherapy in lung cancer, growth of combination immuno oncology regimens, increased focus on biomarker driven therapies, broader use across multiple solid tumors.

The increasing incidence of cancer is expected to propel the growth of the Imfinzi (durvalumab) market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and spread of abnormal cells that can invade and damage normal body tissues. The rising incidence of cancer is largely attributed to an aging population, as cancer risk increases with age, along with lifestyle factors such as smoking, poor dietary habits, and obesity, which contribute to higher cancer rates. Imfinzi (durvalumab) is used in cancer treatment by blocking the PD-L1 protein, thereby preventing cancer cells from escaping immune system detection. For instance, in May 2024, according to the National Cancer Institute (NIH), a US-based government agency, there were 18.1 million cancer survivors in the United States in 2022, a number projected to increase to 22.5 million by 2032. Therefore, the growing incidence of cancer is driving the expansion of the Imfinzi (durvalumab) market.

The rise of personalized medicine is expected to drive the growth of the Imfinzi (durvalumab) market going forward. Personalized medicine is a healthcare approach that customizes treatment strategies based on individual patient characteristics, including genetic profile, environment, and lifestyle, to achieve more precise and effective outcomes. The expansion of personalized medicine is driven by advances in genomic technologies, deeper understanding of molecular biology, increased availability of precision diagnostic tools, and growing demand for targeted therapies that improve outcomes while reducing adverse effects. Imfinzi (durvalumab), through its targeted inhibition of the PD-L1 protein, supports personalized medicine by enabling tailored immunotherapy approaches based on specific tumor biology and immune characteristics, thereby improving treatment effectiveness and minimizing unnecessary side effects. For example, according to the Personalized Medicine Coalition, a US-based representative organization, personalized medicines accounted for 34% of new drug approvals by the FDA in 2022, and represented at least 25% of new approvals over the previous eight years. Therefore, the growth of personalized medicine is fueling the Imfinzi (durvalumab) market.

Major companies operating in the Imfinzi (durvalumab) market are focusing on expanding indications, such as perioperative use in combination with chemotherapy, to strengthen their competitive position. For instance, in January 2023, AstraZeneca plc, a UK-based biopharmaceutical company, announced that IMFINZI combined with chemotherapy more than doubled the pathological complete response rate in patients with resectable early-stage gastric and gastroesophageal junction cancers compared to chemotherapy alone. This approach involved a two-phase treatment strategy, including pre-surgical and post-surgical administration, and demonstrated sustained immune activation benefits. This expansion into gastrointestinal cancer indications highlights AstraZeneca's strategy to broaden its clinical applications and support long-term adoption, although it also introduces regulatory challenges due to the need for additional clinical evidence and health economic assessments for more complex treatment regimens.

Major companies operating in the imfinzi (durvalumab) market are AstraZeneca PLC.

North America was the largest region in the imfinzi (durvalumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the imfinzi (durvalumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the imfinzi (durvalumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The imfinzi (durvalumab) market consists of sales of products including Keytruda, Opdivo, Tecentriq, Libtayo, Bavencio and Emerging PD-1/PD-L1 Inhibitors. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Imfinzi (durvalumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses imfinzi (durvalumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for imfinzi (durvalumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The imfinzi (durvalumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: 2.4mL Injection; 10mL Injection
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By Application: Locally Advanced Urothelial Carcinoma; Metastatic Urothelial Carcinoma; Other Applications
• Companies Mentioned: AstraZeneca PLC.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.